Navigation Links
The First QPatch HT in China Placed in WuXi PharmaTech (NYSE: WX)
Date:5/21/2008

SHANGHAI, China, May 21 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it has acquired a QPatch HT automated patch clamp system, the first unit introduced into China by Sophion Bioscience.

The drug discovery process in pharmaceutical companies begins with identifying potential targets for new diseases. One important class of targets is ion channels that regulate the flow of ions across cellular membranes and therefore influence the physiology of all cells. Patch clamp is a widely applied gold-standard technique for the study of ion channels. Speed and accuracy of automated patch clamp systems are heavily demanded by pharmaceutical companies working with development of ion channel-based drugs.

The newly introduced QPatch HT is the world's first 48-channel gigaseal patch clamp system that can be applied to both voltage-gated and ligand-gated ion channels. With its ability to generate thousands of high-quality data points daily, QPatch HT is enabling new screening paradigms in ion channel drug discovery and safety testing on a truly industrial basis. It is claimed to be taking automated patch clamping to a new and even more powerful level.

"We hope the acquisition of the QPatch technology will assist WuXi PharmaTech in expanding their services into the rapidly increasing fields of cardiac safety testing and ion channel drug discovery," commented Frank Henrichsen, Vice President Sales and Marketing in Sophion Bioscience, the supplier of QPatch HT.

"We are very pleased to have installed the first QPatch HT automated patch clamp system in China, and indeed, the first ever such unit in any integrated drug and medical device R&D outsourcing service company," Dr. Peng Wang, Vice President of Discovery Biology at WuXi PharmaTech, said excitedly, "It will greatly enhance our drug R&D service capabilities and productivity. We will continue investing in cutting-edge discovery technologies as we strive to serve our global clients better."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com .


'/>"/>
SOURCE WuXi PharmaTech
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Crdentia Announces 2008 First Quarter Results
2. DaVita Renal Dietitians Conduct First-Ever EYE on CKD Workshop
3. Cord Blood America Reports First Quarter Financial Results; Gross Profits Increase
4. The Childrens Hospital of Philadelphia Opens the Worlds First Delivery Unit for Mothers Diagnosed with Birth Defects in Fetus
5. Shamir Optical Industry Ltd. to Host Conference Call Announcing First Quarter 2008 Earnings Results
6. First-born babies higher asthma and allergy rates due to pregnancy conditions
7. Baker Energy and Huber Receive First-of-its-Kind Award from Wyoming Department of Environmental Quality
8. Population Health Impact Institute to Host First Methods Evaluation Process(TM) (MEP(TM)) Workshop at Annual CMSA Conference
9. AMDL Announces Teleconference and Audio Web Conference to Discuss First Quarter Financial Results
10. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
11. BMP Sunstone Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... Students interested ... Tissue Donation Awareness Scholarship competition., The winner will earn a $1,000 scholarship and have ... competition begins Feb. 1, and the deadline is May 31, with the winner announced ...
(Date:1/19/2017)... Pittsburgh, PA (PRWEB) , ... January 19, 2017 , ... ... the experience of patients who seek access to the Network’s programs and services in ... requesting primary or specialty care appointments will be offered one for that same afternoon. ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... agency which serves Lawrenceville, New Jersey and the surrounding area, is inaugurating ... lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease or motor neurone ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the second ... Associates of Connecticut (RMACT) have earned “Top Doctor” awards. Dr. Mark Leondires, Dr. ... have each been chosen by their peers for the 2017 list based on ...
(Date:1/19/2017)... ... ... The 21st Century Cures Act’s Impact on Medical Devices:, What You Need ... p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          , What do manufacturers ... year? , The passage of the act means devicemakers will be scrambling to meet ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 Accuray Incorporated (Nasdaq: ... and TomoTherapy® Systems continue to set the bar for ... highest composite overall user satisfaction rating among radiation treatment ... 2016 MD Buyline Market Intelligence Briefing™. The most recent ... composite ratings among industry peers for 11 of the ...
(Date:1/19/2017)... 2017 Shire plc (LSE: SHP, ... Food and Drug Administration (FDA) has acknowledged receipt of ... (NDA) for SHP465, a long-acting, triple-bead, mixed amphetamine salts ... treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is expected ... 2017, the designated Prescription Drug User Fee Act (PDUFA) ...
(Date:1/19/2017)... -- The global  pacemaker market  is expected to reach USD 12.3 ... The heightening prevalence of cardiac conditions coupled with the availability of medical coverage ... technological enhancements in these devices are supporting the expansion of this vertical. ... ... Grand View Research Logo ...
Breaking Medicine Technology: